Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Journal articles and book chapters

08-06-2017 | SGLT2 inhibitors | Article

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

Wysham CH et al. BMC Endocr Disord 2017; 17: 32. doi: 10.1186/s12902-017-0180-8

16-03-2017 | Glycemic control | Review | Article

Metrics for glycemic control: From HbA1c to continuous glucose monitoring

Nat Rev Endocrinol 2017; 13: 425–436. doi: 10.1038/nrendo.2017.3

02-02-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Xu J, Rajaratnam R. Cardiovasc Diabetol 2017; 16: 18. doi: 10.1186/s12933-017-0499-5

21-09-2016 | Heart failure | Article

Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes

Fitchett DH, Udell JA, Inzucchi SE. Eur J Heart Fail 2017; 19: 43–53. doi: 10.1002/ejhf.633

11-08-2016 | Heart failure | Review | Article

Cardiometabolic syndrome and increased risk of heart failure

Von Bibra H, Paulus W, St John Sutton M. Curr Heart Fail Rep 2016; 13: 219–229. doi: 10.1007/s11897-016-0298-4

17-05-2016 | Heart failure | Review | Article

Treating diabetes in patients with heart failure: Moving from risk to benefit

DeFilippis EM, Givertz MM. Curr Heart Fail Rep 2016; 13: 111–118. doi: 10.1007/s11897-016-0291-y

11-01-2016 | Heart failure | Review | Article

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: Systematic review and meta-analysis of randomized and observational studies

Li L et al. BMJ 2016; 352: i610. doi: 10.1136/bmj.i610

29-11-2012 | Post-transplant diabetes mellitus | Review | Article

Management of post-transplant diabetes

Therasse A, Wallia A, Molitch ME. Curr Diab Rep 2013; 13: 121–129. doi: 10.1007/s11892-012-0346-8

Previous
Image Credits